Cargando…

SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy

BACKGROUND: Elevated myocardial intracellular sodium ([Na(+)](i)) was shown to decrease mitochondrial calcium ([Ca(2+)](MITO)) via mitochondrial sodium/calcium exchanger (NCXMITO), resulting in decreased mitochondrial ATP synthesis. The sodium-glucose co-transporter 2 inhibitor (SGLT2i) ertugliflozi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Croteau, Dominique, Baka, Tomas, Young, Sara, He, Huamei, Chambers, Jordan M., Qin, Fuzhong, Panagia, Marcello, Pimentel, David R., Balschi, James A., Colucci, Wilson S., Luptak, Ivan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992115/ https://www.ncbi.nlm.nih.gov/pubmed/36731341 http://dx.doi.org/10.1016/j.biopha.2023.114310

Ejemplares similares

Effects of Sodium‐Glucose Linked Transporter 2 Inhibition With Ertugliflozin on Mitochondrial Function, Energetics, and Metabolic Gene Expression in the Presence and Absence of Diabetes Mellitus in Mice
por: Croteau, Dominique, et al.
Publicado: (2021)

Decreased ATP production and myocardial contractile reserve in metabolic heart disease
por: Luptak, Ivan, et al.
Publicado: (2018)

Differential Effects of Sacubitril/Valsartan on Diastolic Function in Mice With Obesity-Related Metabolic Heart Disease
por: Croteau, Dominique, et al.
Publicado: (2020)

Novel Small-Molecule Troponin Activator Increases Cardiac Contractile Function Without Negative Impact on Energetics
por: He, Huamei, et al.
Publicado: (2021)

Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
por: Fediuk, Daryl J., et al.
Publicado: (2020)

Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes
por: Derosa, Giuseppe, et al.
Publicado: (2018)

Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed‐Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin
por: Sahasrabudhe, Vaishali, et al.
Publicado: (2018)

A novel tracer for in vivo optical imaging of fatty acid metabolism in the heart and brown adipose tissue
por: Panagia, Marcello, et al.
Publicado: (2020)

Overview of Ertugliflozin
por: Nguyen, Vivianne K., et al.
Publicado: (2019)

Pharmacokinetic Properties of Single and Multiple Doses of Ertugliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects
por: Li, Yinhua, et al.
Publicado: (2019)

Altered contractility in mutation-specific hypertrophic cardiomyopathy: A mechano-energetic in silico study with pharmacological insights
por: Forouzandehmehr, Mohamadamin, et al.
Publicado: (2022)

Ertugliflozin for type 2 diabetes [Correction]
Publicado: (2019)

Role of Ertugliflozin in the Management of Diabetes Mellitus
por: Totade, Manisha, et al.
Publicado: (2022)

Evolution of Flight Muscle Contractility and Energetic Efficiency
por: Cao, Tianxin, et al.
Publicado: (2020)

Ertugliflozin in the treatment of type 2 diabetes mellitus
por: Marrs, Joel C, et al.
Publicado: (2020)

Tai Chi Improves Brain Metabolism and Muscle Energetics in Older Adults
por: Zhou, Min, et al.
Publicado: (2018)

Bioequivalence of Metformin in Ertugliflozin/Metformin Fixed‐Dose Combination Tablets to Canadian‐Sourced Metformin Coadministered With Ertugliflozin Under Fasted and Fed States
por: Dawra, Vikas Kumar, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects
por: Li, Yinhua, et al.
Publicado: (2021)

Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations
por: Fediuk, Daryl J., et al.
Publicado: (2021)

End‐to‐end application of model‐informed drug development for ertugliflozin, a novel sodium‐glucose cotransporter 2 inhibitor
por: Fediuk, Daryl J., et al.
Publicado: (2021)

Sodium Glucose Cotransporter 2 (SGLT2) Plays as a Physiological Glucose Sensor and Regulates Cellular Contractility in Rat Mesangial Cells
por: Wakisaka, Masanori, et al.
Publicado: (2016)

Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial
por: Dagogo-Jack, Samuel, et al.
Publicado: (2021)

Obesity modifies the energetic phenotype of dilated cardiomyopathy
por: Rayner, Jennifer J, et al.
Publicado: (2021)

Partial Liver Kinase B1 (LKB1) Deficiency Promotes Diastolic Dysfunction, De Novo Systolic Dysfunction, Apoptosis, and Mitochondrial Dysfunction With Dietary Metabolic Challenge
por: Miller, Edward J., et al.
Publicado: (2015)

Mechanistic complexity of contractile dysfunction in hypertrophic cardiomyopathy
por: Regnier, Michael
Publicado: (2018)

Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date
por: Cinti, Francesca, et al.
Publicado: (2017)

Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus
por: Heymsfield, Steven B., et al.
Publicado: (2020)

Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes
por: Liu, Hongyan, et al.
Publicado: (2021)

Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial
por: Wojeck, Brian S., et al.
Publicado: (2022)

Transgenic Knockdown of Cardiac Sodium/Glucose Cotransporter 1 (SGLT1) Attenuates PRKAG2 Cardiomyopathy, Whereas Transgenic Overexpression of Cardiac SGLT1 Causes Pathologic Hypertrophy and Dysfunction in Mice
por: Ramratnam, Mohun, et al.
Publicado: (2014)

Gestation changes sodium pump isoform expression, leading to changes in ouabain sensitivity, contractility, and intracellular calcium in rat uterus
por: Floyd, Rachel V., et al.
Publicado: (2017)

Energetics of Coupled Active Transport of Sodium and Chloride
por: Martin, Duncan W., et al.
Publicado: (1966)

The role of contractile dyssynchrony in pacing-induced cardiomyopathy: detailed assessment using index of contractile asymmetry
por: Fruelund, Patricia Zerlang, et al.
Publicado: (2023)

Cardiomyopathies and Related Changes in Contractility of Human Heart Muscle
por: Vikhorev, Petr G., et al.
Publicado: (2018)

The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus
por: Sahasrabudhe, V., et al.
Publicado: (2017)

Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects
por: Dawra, Vikas Kumar, et al.
Publicado: (2018)

Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus
por: Liu, Jie, et al.
Publicado: (2020)

Population Pharmacokinetic Model for Ertugliflozin in Healthy Subjects and Patients With Type 2 Diabetes Mellitus
por: Fediuk, Daryl J., et al.
Publicado: (2020)

Efficacy and Safety of Ertugliflozin in Type 2 Diabetes: A Systematic Review and Meta-Analysis
por: Liu, Li, et al.
Publicado: (2022)

Creatine Kinase-Overexpression Improves Myocardial Energetics, Contractile Dysfunction and Survival in Murine Doxorubicin Cardiotoxicity
por: Gupta, Ashish, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_j6eb42mj4ssuopuvhf2a5h5e0m